These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28625018)

  • 1. No Pharmacokinetic Interaction Between the Hepatitis C Virus Inhibitors Elbasvir/Grazoprevir and Famotidine or Pantoprazole.
    Feng HP; Vaddady P; Guo Z; Liu F; Panebianco D; Levine V; Caro L; Butterton JR; Iwamoto M; Yeh WW
    Clin Transl Sci; 2017 Sep; 10(5):360-365. PubMed ID: 28625018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
    Feng HP; Caro L; Fandozzi C; Chu X; Guo Z; Talaty J; Panebianco D; Dunnington K; Du L; Hanley WD; Fraser IP; Mitselos A; Denef JF; De Lepeleire I; de Hoon JN; Vandermeulen C; Marshall WL; Jumes P; Huang X; Martinho M; Valesky R; Butterton JR; Iwamoto M; Yeh WW
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel.
    Marshall WL; Feng HP; Caro L; Talaty J; Guo Z; Huang X; Panebianco D; Ma J; Mangin E; O'Reilly TE; Butterton JR; Yeh WW
    Eur J Clin Pharmacol; 2017 May; 73(5):593-600. PubMed ID: 28233047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.
    Feng HP; Guo Z; Ross LL; Fraser I; Panebianco D; Jumes P; Fandozzi C; Caro L; Talaty J; Ma J; Mangin E; Huang X; Marshall WL; Butterton JR; Iwamoto M; Yeh WW
    J Antimicrob Chemother; 2019 Mar; 74(3):710-717. PubMed ID: 30541077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct-Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse-Transcriptase Inhibitor Tenofovir Disoproxil Fumarate.
    Feng HP; Guo Z; Caro L; Talaty JE; Mangin E; Panebianco D; Fandozzi C; Zhu Y; Marshall W; Huang X; Hanley WD; Jumes P; Valesky R; Martinho M; Butterton JR; Iwamoto M; Yeh WW
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):962-970. PubMed ID: 31173674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Pharmacokinetics and Drug-Drug Interactions of Elbasvir/Grazoprevir.
    Kiang TKL
    Eur J Drug Metab Pharmacokinet; 2018 Oct; 43(5):509-531. PubMed ID: 29557529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir.
    Ankrom W; Sanchez RI; Yee KL; Fan L; Mitra P; Wolford D; Triantafyllou I; Sterling LM; Stoch SA; Iwamoto M; Khalilieh S
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants.
    Cheung TT; Yan Chiu JW; Yuen MF; Ling Lam KS; Yung Cheung BM; Feng HP; Yeh WW; Wang J; Li W; Zhao XM; Wang Z; Mu S
    Clin Ther; 2018 May; 40(5):719-732.e1. PubMed ID: 29724498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
    Kwo P; Gane EJ; Peng CY; Pearlman B; Vierling JM; Serfaty L; Buti M; Shafran S; Stryszak P; Lin L; Gress J; Black S; Dutko FJ; Robertson M; Wahl J; Lupinacci L; Barr E; Haber B
    Gastroenterology; 2017 Jan; 152(1):164-175.e4. PubMed ID: 27720838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Grazoprevir/elbasvir fixed-dose combination for hepatitis C.
    Gamal N; Andreone P
    Drugs Today (Barc); 2016 Jul; 52(7):377-85. PubMed ID: 27540596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
    Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
    Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment.
    Caro L; Wenning L; Feng HP; Guo Z; Du L; Bhagunde P; Fandozzi C; Panebianco D; Marshall WL; Butterton JR; Iwamoto M; Yeh WW
    Eur J Clin Pharmacol; 2019 May; 75(5):665-675. PubMed ID: 30680407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic similarity demonstrated after crushing of the elbasvir/grazoprevir fixed-dose combination tablet for HCV infection.
    Pijnenburg DWM; van Seyen M; Abbink EJ; Colbers A; Drenth JPH; Burger DM
    J Antimicrob Chemother; 2020 Sep; 75(9):2661-2665. PubMed ID: 32544221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.
    Asante-Appiah E; Curry S; McMonagle P; Ingravallo P; Chase R; Nickle D; Qiu P; Howe A; Lahser FC
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Grazoprevir + elbasvir for the treatment of hepatitis C virus infection.
    Alric L; Bonnet D
    Expert Opin Pharmacother; 2016; 17(5):735-42. PubMed ID: 26933896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.
    Lahser FC; Bystol K; Curry S; McMonagle P; Xia E; Ingravallo P; Chase R; Liu R; Black T; Hazuda D; Howe AY; Asante-Appiah E
    Antimicrob Agents Chemother; 2016 May; 60(5):2954-64. PubMed ID: 26926625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
    Sulkowski M; Hezode C; Gerstoft J; Vierling JM; Mallolas J; Pol S; Kugelmas M; Murillo A; Weis N; Nahass R; Shibolet O; Serfaty L; Bourliere M; DeJesus E; Zuckerman E; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
    Lancet; 2015 Mar; 385(9973):1087-97. PubMed ID: 25467560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C.
    Sulejmani N; Jafri SM; Gordon SC
    Expert Opin Drug Metab Toxicol; 2016; 12(3):353-61. PubMed ID: 26849059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial.
    Boerekamps A; De Weggheleire A; van den Berk GE; Lauw FN; Claassen MAA; Posthouwer D; Bierman WF; Hullegie SJ; Popping S; van de Vijver DACM; Dofferhoff ASM; Kootstra GJ; Leyten EM; den Hollander J; van Kasteren ME; Soetekouw R; Ammerlaan HSM; Schinkel J; Florence E; Arends JE; Rijnders BJA
    Lancet Gastroenterol Hepatol; 2019 Apr; 4(4):269-277. PubMed ID: 30660617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy.
    Feng HP; Guo Z; Caro L; Marshall WL; Liu F; Panebianco D; Vaddady P; Barbour A; Reitmann C; Jumes P; Gilmartin J; Wolford D; Valesky R; Martinho M; Butterton JR; Iwamoto M; Fraser I; Webster L; Yeh WW
    Clin Transl Sci; 2018 Nov; 11(6):562-572. PubMed ID: 30040871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.